{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004946","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.051475+00:00","generated_at":"2026-06-12T08:50:13.261012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics Q2 net loss $11.3M; BTC top-line data pushed to H2 2024","bullets":["Net loss of $11.3M ($0.09/share) in Q2 2023 vs $8.5M loss ($0.08/share) in Q2 2022.","Cash and marketable securities $169M as of June 30, 2023; cash runway into 2026.","R&D expense $10.2M in Q2 2023, up 74% YoY driven by CTX-009 clinical and manufacturing costs.","CTX-009 Phase 2 CRC initial data still expected H2 2023; BTC top-line data delayed to H2 2024 due to slower enrollment.","CTX-8371 (PD-1 x PD-L1) IND submission targeted Q3 2023 with Phase 1 start in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004946","json":"https://secwatch.observer/filing/0001171843-23-004946.json","markdown":"https://secwatch.observer/filing/0001171843-23-004946.md","text":"https://secwatch.observer/filing/0001171843-23-004946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/0001171843-23-004946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/f8k_080223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:50:13.261012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32fcd415137533dee3945722cc754eae901bca15","claim":"Compass Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, EPS $0.09 per common share.","evidence_excerpt":"On August 3, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/0001171843-23-004946-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share"},{"label":"EPS","value":"$0.09 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}